A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Wake Forest University Health Sciences
Sykehuset Innlandet HF
National Cancer Institute (NCI)
Gilead Sciences
Henan Cancer Hospital
National Institutes of Health Clinical Center (CC)
Hackensack Meridian Health
Children's Oncology Group
Novartis
Otsuka Pharmaceutical Co., Ltd.
Fred Hutchinson Cancer Center
Chipscreen Biosciences, Ltd.
Calibr, a division of Scripps Research
University College, London
University of California, Davis
University of Colorado, Denver
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Hackensack Meridian Health
Hackensack Meridian Health
National Cancer Institute (NCI)
Artiva Biotherapeutics, Inc.
Geneve TEAM Ambulances
CRISPR Therapeutics
University Hospital, Caen
University Hospital, Caen
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
University Hospital, Toulouse
University of Nebraska
H. Lee Moffitt Cancer Center and Research Institute
Washington University School of Medicine
Stanford University
Canadian Cancer Trials Group
Canadian Cancer Trials Group
University of Michigan
National Heart, Lung, and Blood Institute (NHLBI)
BeOne Medicines
Hospital Universitario Dr. Jose E. Gonzalez
Zhejiang Cancer Hospital
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
The First Hospital of Jilin University
University of Massachusetts, Amherst
Thomas Jefferson University
Gilead Sciences
Aptarion Biotech AG
Dana-Farber Cancer Institute
Pharmacyclics LLC.